Tubacin yielded an IC50 of 1.52 μM for intracellular infectious virus titers in JEV-infected human cerebellar medulloblastoma TE671 cells compared with untreated infected cells. In T24 cells, Tubacin produced a dose-dependent decrease in viability. In unloaded chondrocytes without IL-1β, Tubacin increased acetylated α-tubulin expression. Tubacin pretreatment yielded an IC50 of 1.89 μM for SRIP-driven EGFP reporter fluorescence in TE671 cell monolayers compared with untreated infected cells. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Tubacin effects on intracellular infectious virus titers
Cell-based study · Human cerebellar medulloblastoma TE671 cells [1]
Human cerebellar medulloblastoma TE671 cells infected with JEV were treated with Tubacin for 36 h. Compared with untreated infected cells, Tubacin had an IC50 of 1.52 μM for intracellular infectious virus titers.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 5, and 10 μM
- Exposure duration
- 36 h treatment
- Co-treatment
- Other interventions in this design: JEV. Compound effect isolated by the comparison: infected cells treated with or without tubacin.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Tubacin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Antiviral Activity of Pan- and Selective-HDAC Inhibitors Against JEV (S10); 4. Methods and Materials > 4.1. Cells and Virus (S40); 4. Methods and Materials > 4.4. Quantitative Assays of Virus Yield and Intracellular Viral Titer (S60); Figure 3 legend (S102, S104, S105)
intracellular infectious virus titers: intracellular infectious virus titers; comparator: untreated infected cells — 2. Results > 2.1. Antiviral Activity of Pan- and Selective-HDAC Inhibitors Against JEV (S10)
Tubacin effects on cell viability
Cell-based study · T24 cells [2]
In T24 cells, Tubacin treatment at micromolar concentrations produced a dose-dependent decrease in cell viability at 24 h and 72 h.
Literature-Reported Treatment Conditions
- Treatment concentration
- micromolar concentrations
- Exposure duration
- 24 h and 72 h
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Tubacin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Reagents (S5); Materials and methods > Cell viability assay (S8); Results > The selective HDAC6i tubacin radiosensitizes human bladder cancer cells (S98, S99); Fig. 3 legend (S173, S180)
viability of T24 cells: viability of T24 cells; comparator: control — Results > The selective HDAC6i tubacin radiosensitizes human bladder cancer cells (S99); Fig. 3 legend (S173)
Tubacin effects on acetylated α-tubulin expression
Cell-based study · chondrocytes [3]
In unloaded cells, in the absence of IL-1β, treatment with tubacin (0.5 μM) for 24 h increased expression of acetylated α-tubulin.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 μM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle, control.
Methods and source locations
Compound reported in the paper: Tubacin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Inhibition of HDAC6 restores cilia elongation and blocks the anti-inflammatory effects of mechanical loading in the presence of IL-1β (S119); Results > In unloaded cells, pharmaceutical inhibition of IL-1β mediated tubulin acetylation suppresses inflammatory signalling and cilia elongation (S136)
expression of acetylated α-tubulin: expression of acetylated α-tubulin — Results > In unloaded cells, pharmaceutical inhibition of IL-1β mediated tubulin acetylation suppresses inflammatory signalling and cilia elongation (S136)
Tubacin effects on reporter fluorescence in a pretreatment assay
Cell-based study · TE671 cells monolayer [1]
TE671 cell monolayers were pretreated with Tubacin for 1 h before JEV SRIP infection. Compared with untreated infected cells, Tubacin had an IC50 of 1.89 μM for green fluorescence intensity of the SRIP-driven EGFP reporter.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 5, and 10 μM
- Exposure duration
- pretreated with tubacin (0, 1, 5, and 10 μM) for 1 h; 36 h post infection
- Co-treatment
- Other interventions in this design: JEV SRIPs 10 TCID50. Compound effect isolated by the comparison: compared with untreated infected cells.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Tubacin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. Preventive and Therapeutic Activities of Tubacin against JEV Infection (S20); 4. Methods and Materials > 4.6. Time-of-Addition Assay (S73, S74); Figure 5 legend (S114); Figure 7 legend (S121)
green fluorescence intensity of SRIP-driven EGFP reporter: green fluorescence intensity of SRIP-driven EGFP reporter; comparator: untreated infected cells — 2. Results > 2.2. Preventive and Therapeutic Activities of Tubacin against JEV Infection (S20)